Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: Results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia

British Journal of Haematology

Volumn 164, Issue 2, 2014, Pages 223-232

  Deininger, Michael W ^a,l   Kopecky, Kenneth J ^b,c   Radich, Jerald P ^c   Kamel Reid, Suzanne ^d   Stock, Wendy ^e   Paietta, Elisabeth ^f   Emanuel, Peter D ^g   Tallman, Martin ^h   Wadleigh, Martha ⁱ   Larson, Richard A ^e   Lipton, Jeffrey H ^j   Slovak, Marilyn L ^k,m   Appelbaum, Frederick R ^c   Druker, Brian J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b SWOG STATISTICAL CENTER   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY OF CHICAGO   (United States)

^f MONTEFIORE MEDICAL CENTER   (United States)

^g UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j UNIVERSITY HEALTH NETWORK   (Canada)

^k CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^l UNIVERSITY OF UTAH   (United States)

^m SONORA QUEST LABORATORIES   (United States)

more..

Author keywords

BCR ABL1; Chronic myeloid leukaemia; Imatinib

Indexed keywords

CREATINE KINASE; HEMOGLOBIN; IMATINIB; MESSENGER RNA;

ADULT; AGED; ANOREXIA; ARTICLE; BCR ABL1 GENE; BLOOD TOXICITY; BONE PAIN; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CYTOGENETICS; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK DISEASE; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; MALE; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPHIL; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RASH; THROMBOCYTE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR GENE; URINARY TRACT INFECTION; VERY ELDERLY; VOMITING;

BCR-ABL1; CHRONIC MYELOID LEUKAEMIA; IMATINIB;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZAMIDES; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84891628299     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12618     Document Type: Article

References (30)

1. Baccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., Cervantes, F., Deininger, M., Gratwohl, A., Guilhot, F., Hochhaus, A., Horowitz, M., Hughes, T., Kantarjian, H., Larson, R., Radich, J., Simonsson, B., Silver, R.T., Goldman, J. & Hehlmann, R. (2009a) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. Journal of Clinical Oncology, 27, 6041-6051.
2. Baccarani, M., Rosti, G., Castagnetti, F., Haznedaroglu, I., Porkka, K., Abruzzese, E., Alimena, G., Ehrencrona, H., Hjorth-Hansen, H., Kairisto, V., Levato, L., Martinelli, G., Nagler, A., Lanng Nielsen, J., Ozbek, U., Palandri, F., Palmieri, F., Pane, F., Rege-Cambrin, G., Russo, D., Specchia, G., Testoni, N., Weiss-Bjerrum, O., Saglio, G. & Simonsson, B. (2009b) Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood, 113, 4497-4504.
3. Castagnetti, F., Palandri, F., Amabile, M., Testoni, N., Luatti, S., Soverini, S., Iacobucci, I., Breccia, M., Rege Cambrin, G., Stagno, F., Specchia, G., Galieni, P., Iuliano, F., Pane, F., Saglio, G., Alimena, G., Martinelli, G., Baccarani, M. & Rosti, G. (2009) Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. Blood, 113, 3428-3434.
4. Cortes, J.E., Kantarjian, H.M., Goldberg, S.L., Powell, B.L., Giles, F.J., Wetzler, M., Akard, L., Burke, J.M., Kerr, R., Saleh, M., Salvado, A., McDougall, K., Albitar, M. & Radich, J. (2009) High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. Journal of Clinical Oncology, 27, 4754-4759.
5. Cortes, J.E., Baccarani, M., Guilhot, F., Druker, B.J., Branford, S., Kim, D.W., Pane, F., Pasquini, R., Goldberg, S.L., Kalaycio, M., Moiraghi, B., Rowe, J.M., Tothova, E., De Souza, C., Rudoltz, M., Yu, R., Krahnke, T., Kantarjian, H.M., Radich, J.P. & Hughes, T.P. (2010) Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. Journal of Clinical Oncology, 28, 424-430.
6. Deininger, M., Buchdunger, E. & Druker, B.J. (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood, 105, 2640-2653.
7. Deininger, M., O'Brien, S.G., Guilhot, F., Goldman, J.M., Hochhaus, A., Hughes, T.P., Radich, J.P., Hatfield, A.K., Mone, M., Filian, J., Reynolds, J., Gathmann, I., Larson, R.A. & Druker, B.J. (2009) International randomized study of interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood (ASH Annual Meeting Abstracts), 114, 1126.
8. Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S. & Sawyers, C.L. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine, 344, 1031-1037.
9. Druker, B.J., Guilhot, F., O'Brien, S.G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M.W., Silver, R.T., Goldman, J.M., Stone, R.M., Cervantes, F., Hochhaus, A., Powell, B.L., Gabrilove, J.L., Rousselot, P., Reiffers, J., Cornelissen, J.J., Hughes, T., Agis, H., Fischer, T., Verhoef, G., Shepherd, J., Saglio, G., Gratwohl, A., Nielsen, J.L., Radich, J.P., Simonsson, B., Taylor, K., Baccarani, M., So, C., Letvak, L. & Larson, R.A. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine, 355, 2408-2417.
10. Hanfstein, B., Muller, M.C., Hehlmann, R., Erben, P., Lauseker, M., Fabarius, A., Schnittger, S., Haferlach, C., Gohring, G., Proetel, U., Kolb, H.J., Krause, S.W., Hofmann, W.K., Schubert, J., Einsele, H., Dengler, J., Hanel, M., Falge, C., Kanz, L., Neubauer, A., Kneba, M., Stegelmann, F., Pfreundschuh, M., Waller, C.F., Branford, S., Hughes, T.P., Spiekermann, K., Baerlocher, G.M., Pfirrmann, M., Hasford, J., Saussele, S. & Hochhaus, A. (2012) Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia, 26, 2096-2102.
11. Hasford, J., Pfirrmann, M., Hehlmann, R., Allan, N.C., Baccarani, M., Kluin-Nelemans, J.C., Alimena, G., Steegmann, J.L. & Ansari, H. (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. Journal of the National Cancer Institute, 90, 850-858.
12. Hehlmann, R., Lauseker, M., Jung-Munkwitz, S., Leitner, A., Muller, M.C., Pletsch, N., Proetel, U., Haferlach, C., Schlegelberger, B., Balleisen, L., Hanel, M., Pfirrmann, M., Krause, S.W., Nerl, C., Pralle, H., Gratwohl, A., Hossfeld, D.K., Hasford, J., Hochhaus, A. & Saussele, S. (2011) Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-{alpha} in newly diagnosed chronic myeloid leukemia. Journal of Clinical Oncology, 29, 1634-1642.
13. Hughes, T.P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M.L., Gathmann, I., Bolton, A.E., van Hoomissen, I.C., Goldman, J.M. & Radich, J.P. (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. New England Journal of Medicine, 349, 1423-1432.
14. Hughes, T.P., Hochhaus, A., Branford, S., Muller, M.C., Kaeda, J.S., Foroni, L., Druker, B.J., Guilhot, F., Larson, R.A., O'Brien, S.G., Rudoltz, M.S., Mone, M., Wehrle, E., Modur, V., Goldman, J.M. & Radich, J.P. (2010) Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood, 116, 3758-3765.
15. Kantarjian, H.M., Talpaz, M., O'Brien, S., Giles, F., Garcia-Manero, G., Faderl, S., Thomas, D., Shan, J., Rios, M.B. & Cortes, J. (2003) Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood, 101, 473-475.
16. Kantarjian, H., Talpaz, M., O'Brien, S., Garcia-Manero, G., Verstovsek, S., Giles, F., Rios, M.B., Shan, J., Letvak, L., Thomas, D., Faderl, S., Ferrajoli, A. & Cortes, J. (2004) High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood, 103, 2873-2878.
17. Kantarjian, H., Shah, N.P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., Nakamae, H., Huguet, F., Boque, C., Chuah, C., Bleickardt, E., Bradley-Garelik, M.B., Zhu, C., Szatrowski, T., Shapiro, D. & Baccarani, M. (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine, 362, 2260-2270.
18. Kantarjian, H.M., Hochhaus, A., Saglio, G., De Souza, C., Flinn, I.W., Stenke, L., Goh, Y.T., Rosti, G., Nakamae, H., Gallagher, N.J., Hoenekopp, A., Blakesley, R.E., Larson, R.A. & Hughes, T.P. (2011) Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncology, 12, 841-851.
19. Kantarjian, H.M., Shah, N.P., Cortes, J.E., Baccarani, M., Agarwal, M.B., Undurraga, M.S., Wang, J., Ipina, J.J., Kim, D.W., Ogura, M., Pavlovsky, C., Junghanss, C., Milone, J.H., Nicolini, F.E., Robak, T., Van Droogenbroeck, J., Vellenga, E., Bradley-Garelik, M.B., Zhu, C. & Hochhaus, A. (2012) Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood, 119, 1123-1129.
20. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
21. Larson, R.A., Druker, B.J., Guilhot, F., O'Brien, S.G., Riviere, G.J., Krahnke, T., Gathmann, I. & Wang, Y. (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood, 111, 4022-4028.
22. de Lavallade, H., Apperley, J.F., Khorashad, J.S., Milojkovic, D., Reid, A.G., Bua, M., Szydlo, R., Olavarria, E., Kaeda, J., Goldman, J.M. & Marin, D. (2008) Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. Journal of Clinical Oncology, 26, 3358-3363.
23. Lucas, C.M., Wang, L., Austin, G.M., Knight, K., Watmough, S.J., Shwe, K.H., Dasgupta, R., Butt, N.M., Galvani, D., Hoyle, C.F., Seale, J.R. & Clark, R.E. (2008) A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia, 22, 1963-1966.
24. Mantel, N. (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Reports, 50, 163-170.
25. Marin, D., Hedgley, C., Clark, R.E., Apperley, J., Foroni, L., Milojkovic, D., Pocock, C., Goldman, J.M. & O'Brien, S. (2012a) Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood, 120, 291-294.
26. Marin, D., Ibrahim, A.R., Lucas, C., Gerrard, G., Wang, L., Szydlo, R.M., Clark, R.E., Apperley, J.F., Milojkovic, D., Bua, M., Pavlu, J., Paliompeis, C., Reid, A., Rezvani, K., Goldman, J.M. & Foroni, L. (2012b) Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Journal of Clinical Oncology, 30, 232-238.
27. Preudhomme, C., Guilhot, J., Nicolini, F.E., Guerci-Bresler, A., Rigal-Huguet, F., Maloisel, F., Coiteux, V., Gardembas, M., Berthou, C., Vekhoff, A., Rea, D., Jourdan, E., Allard, C., Delmer, A., Rousselot, P., Legros, L., Berger, M., Corm, S., Etienne, G., Roche-Lestienne, C., Eclache, V., Mahon, F.X. & Guilhot, F. (2010) Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. New England Journal of Medicine, 363, 2511-2521.
28. Radich, J.P., Kopecky, K.J., Appelbaum, F.R., Kamel-Reid, S., Stock, W., Malnassy, G., Paietta, E., Wadleigh, M., Larson, R.A., Emanuel, P., Tallman, M., Lipton, J., Turner, A.R. & Druker, B.J. (2012) A randomized trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic phase chromic myeloid leukemia. Blood, 120, 3898-3905.
29. Saglio, G., Kim, D.W., Issaragrisil, S., Le, C.P., Etienne, G., Lobo, C., Pasquini, R., Clark, R.E., Hochhaus, A., Hughes, T.P., Gallagher, N., Hoenekopp, A., Dong, M., Haque, A., Larson, R.A. & Kantarjian, H.M. (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. New England Journal of Medicine, 362, 2251-2259.
30. Sawyers, C.L. (1999) Chronic myeloid leukemia. New England Journal of Medicine, 340, 1330-1340.